Challenges in clinical prostate cancer: Role of imaging

American Journal of Roentgenology

Volumn 192, Issue 6, 2009, Pages 1455-1470

  Kelloff, Gary J ^a   Choyke, Peter ^a   Coffey, Donald S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diffusion weighted MRI; Dynamic contrast enhanced MRI; FDG PET imaging; Functional imaging; High intensity focused ultrasound imaging; MRI; Prostate cancer imaging; SPECT

Indexed keywords

3' FLUORO 3' DEOXYTHYMIDINE F 18; ANTI 1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID F 18; ANTINEOPLASTIC AGENT; CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROTESTOSTERONE F 18; MEDRONATE TECHNETIUM TC 99M; MIP 1095; PROSTATE SPECIFIC ANTIGEN; SODIUM FLUORIDE F 18; TRACER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BONE METASTASIS; CANCER RELAPSE; CANCER STAGING; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LETHALITY; LYMPH NODE METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RAMAN SPECTROMETRY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNOLOGY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE; COMPUTER ASSISTED SURGERY; CONFERENCE PAPER; IMAGE ENHANCEMENT; MALE; METHODOLOGY; PROSTATE TUMOR;

DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; MALE; PROSTATIC NEOPLASMS; SURGERY, COMPUTER-ASSISTED;

EID: 67049159514     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.2579     Document Type: Review

References (102)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96
2. Kundra V, Silverman PM, Matin SF, Choi H. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. AJR 2007; 189:830-844 (Pubitemid 47479765)
3. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61:110-117
4. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168:273-280
5. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44:549-555 (Pubitemid 39663421)
6. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169:1337-1340
7. 18F-fluorocholine PET. J Nucl Med 2006; 47:262-269
8. Albrecht S, Buchegger F, Soloviev D, et al. (11) C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34:185-196 (Pubitemid 46147501)
9. Linden RA, Halpern EJ. Advances in transrectal ultrasound imaging of the prostate. Semin Ultrasound CT MR 2007; 28:249-257 (Pubitemid 47187637)
10. Feleppa EJ, Alam SK, Deng CX. Emerging ultrasound technologies for early markers of disease. Dis Markers 2002; 18:249-268 (Pubitemid 38016224)
11. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999; 213:473-480 (Pubitemid 29510595)
12. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22:2790-2799 (Pubitemid 41079896)
13. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002; 16:451-463 (Pubitemid 35167879)
14. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994; 193:703-709 (Pubitemid 24366938)
15. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57:108-111 (Pubitemid 32065829)
16. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36:31-35 (Pubitemid 29265277)
17. Turlakow A, Larson SM, Coakley F, et al. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 2001; 45:235-244 (Pubitemid 34182905)
18. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4:99-104 (Pubitemid 34272714)
19. Akin O, Hricak H. Imaging of prostate cancer. Radiol Clin North Am 2007; 45:207-222 (Pubitemid 44854046)
20. Saokar A, Braschi M, Harisinghani M. Lymphotrophic nanoparticle enhanced MR imaging (LNMRI) for lymph node imaging. Abdom Imaging 2006; 31:660-667 (Pubitemid 46723637)
21. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243:28-53 (Pubitemid 46579693)
22. Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiol 2008; 49:107-120
23. Pucar D, Sella T, Schoder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008; 18:87-97 (Pubitemid 350307537)
24. Shukla-Dave A, Hricak H, Scardino PT. Imaging low-risk prostate cancer. Curr Opin Urol 2008; 18:78-86 (Pubitemid 350307536)
25. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112:1650-1659
26. Wright JL, Lange PH. Newer potential biomarkers in prostate cancer. Rev Urol 2007; 9:207-213
27. Bostwick DG. Prostate-specific antigen: current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994; 102[4 suppl 1]:S31-S37 (Pubitemid 24345581)
28. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003; 30:677-686 (Pubitemid 37485185)
29. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8:268-278
30. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58:673-684 (Pubitemid 40956818)
31. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007; 99:786-793 (Pubitemid 46439567)
32. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169:517-523
33. Rubin MA, Loda M. Prostate cancer: molecular pathology and biologic determinants. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FM, eds. Comprehensive textbook of genitourinary oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2005
34. Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate 1999; 40:261-268 (Pubitemid 29398053)
35. Shariat SF, Scardino PT, Lilja H. Screening for prostate cancer: an update. Can J Urol 2008; 15:4363-4374
36. Eichelberger LE, Cheng L. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 2004; 100:2573-2576
37. Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology 2008; 72:177-182
38. Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 2005; 104:2373-2383 (Pubitemid 41691558)
39. Balaji KC, Fair WR, Feleppa EJ, et al. Role of advanced 2 and 3-dimensional ultrasound for detecting prostate cancer. J Urol 2002; 168:2422-2425 (Pubitemid 35402631)
40. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234:804-814 (Pubitemid 40250824)
41. Weinreb J. ACRIN 6659: MRI and MRSI of prostate cancer prior to radical prostatectomy - a prospective multi-institutional clinicopathological study. (abstr. No. SSJ05-SSJ06) Proceedings of the Radiological Society of North America (RSNA) 92nd annual scientific assembly and annual meeting. Chicago, IL: RSNA, 2006
42. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006; 66:10855-10860
43. Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T: initial experience. Magn Reson Med 2007; 58:1099-1106 (Pubitemid 350234196)
44. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233:441-448 (Pubitemid 39423803)
45. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004; 20:654-661 (Pubitemid 39313742)
46. Shimofusa R, Fujimoto H, Akamata H, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005; 29:149-153 (Pubitemid 40411296)
47. 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 2008; 246:480-488
48. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr 2006; 30:7-11 (Pubitemid 43052291)
49. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results. Radiology 2007; 245:176-185 (Pubitemid 47417801)
50. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199:751-756 (Pubitemid 26157479)
51. Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 2006; 107:439-450 (Pubitemid 44107202)
52. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008; 18:71-77 (Pubitemid 350307535)
53. Zhou H, Resnick MI. Molecular image validation utilizing the correlation of histopathology and marker placement system (CHAMPS) protocol. (abstr) Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO) 48th annual meeting. Philadelphia, PA, 2006:A2269
54. Tokuda J, Fischer GS, Csoma C, et al. Software strategy for robotic transperineal prostate therapy in closed-bore MRI. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv 2008; 11(Pt 2):701-709
55. Barnes AS, Haker SJ, Mulkern RV, So M, D'Amico AV, Tempany CM. Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology 2005; 66:1319 (Pubitemid 41797318)
56. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007; 63:335-350 (Pubitemid 47321040)
57. Mulkern RV, Barnes AS, Haker SJ, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006; 24:563-568 (Pubitemid 43776563)
58. Larson SM, Schoder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol 2008; 18:65-70 (Pubitemid 350307534)
59. Saksena MA, Saokar A, Harisinghani MG. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging. Eur J Radiol 2006; 58:367-374 (Pubitemid 43729065)
60. Muntener M, Patriciu A, Petrisor D, et al. Transperineal prostate intervention: robot for fully automated MR imaging - system description and proof of principle in a canine model. Radiology 2008; 247:543-549
61. Barqawi AB, Crawford ED. Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer. Oncology (Williston Park) 2008; 22:123-129
62. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713-725 (Pubitemid 24141165)
63. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003; 62:86-91 (Pubitemid 36802077)
64. Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol 2003; 43:12-27 (Pubitemid 36134310)
65. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170:1872-1876 (Pubitemid 37254948)
66. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597 (Pubitemid 29211767)
67. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17:1499-1507 (Pubitemid 29220858)
68. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165:1146-1151 (Pubitemid 32210224)
69. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98:715-717 (Pubitemid 43821789)
70. Oh J, Colberg JW, Ornstein DK, et al. Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists. J Urol 1999; 161:520-523
71. Leibman BD, Dillioglugil O, Wheeler TM, Scardino PT. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate-specific antigen level. Cancer 1995; 76:2530-2534
72. Hanlon AL, Moore DF, Hanks GE. Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma. Cancer 1998; 83:130-134 (Pubitemid 28299638)
73. Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005; 173:797-802 (Pubitemid 40239344)
74. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95:1376-1383 (Pubitemid 37220457)
75. 18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005; 11:4761-4769
76. Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006; 24:2513-2519 (Pubitemid 46630628)
77. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48:56-63
78. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003; 21:1715-1721 (Pubitemid 46638582)
79. 18F]DCFBC: a new imag ing probe for prostate cancer. Clin Cancer Res 2008; 14:3036-3043
80. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008; 51:4504-4517
81. Chen Y, Foss CA, Byun Y, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008; 51:7933-7943
82. Molecular Insight Pharmaceuticals Website. Molecular Insight presents three studies on Trofex program for prostate cancer diagnosis and staging. www.molecularinsight.com/pressreleases/20080618-2.aspx. Accessed June 18, 2008
83. Lee Z, Sodee DB, Resnick M, Maclennan GT. Multimodal and three-dimensional imaging of prostate cancer. Comput Med Imaging Graph 2005; 29:477-486 (Pubitemid 41247792)
84. 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297
85. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40:1623-1629 (Pubitemid 29471151)
86. Westphalen AC, McKenna DA, Kurhanewicz J, Coakley F. Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J Endourol 2008; 22:789-794 (Pubitemid 351550760)
87. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:425-430
88. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499 (Pubitemid 36706536)
89. Freedland SJ, Moul JW. Prostate-specific antigen recurrence after definitive therapy. J Urol 2007; 177:1985-1991 (Pubitemid 46726405)
90. Loberg RD, Fielhauer JR, Pienta BA, et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 2003; 62[suppl 1]:128-133 (Pubitemid 41116571)
91. D'Amico, A. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective - identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. BJU Int 2007; 99[suppl 1]:13-16; discussion 17-18 (Pubitemid 44952822)
92. Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Front Biosci 2007; 12:3273-3286
93. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32:344-350 (Pubitemid 40562127)
94. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001; 22:963-969 (Pubitemid 32783446)
95. Oyama N, Kim J, Jones LA, et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol 2002; 29:783-790 (Pubitemid 35346897)
96. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34:274-292 (Pubitemid 39365998)
97. Valicenti RK, Sweet JW, Hauck WW, et al. Variation of clinical target volume definition in three-dimensional conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44:931-935 (Pubitemid 29284144)
98. Lee KC, Sud S, Meyer CR, et al. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 2007; 67:3524-3528 (Pubitemid 46762131)
99. Lee KC, Bradley DA, Hussain M, et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007; 9:1003-1011 (Pubitemid 350255347)
100. 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging 2006; 33:491-494
101. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95:981-989 (Pubitemid 36896715)
102. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol 2002; 168:491-495 (Pubitemid 34793279)